Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioterrorism
Reports summarize bioterrorism study results from SIGA Technologies, Inc.
March 22nd, 2008
Research findings, 'Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company,' are discussed in a new report. "The unmet need for effective antivirals against potential agents of bioterrorism and emerging infections is obvious; however, the challenges to develop such drugs are daunting. Even with the passage of Project BioShield and more recently the BARDA legislation, there is still not a clear market for these types of drugs and limited federal funding available to support expensive drug development studies. SIGA Technologies, Inc. is a small biotech company committed to developing novel products for the prevention and treatment of severe...
Source: Law & Health Weekly (2008-03-22)
|
